Vukasin Paunovich Sells 42,067 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 42,067 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the transaction, the chief technology officer directly owned 205,379 shares of the company’s stock, valued at $2,643,227.73. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vukasin Paunovich also recently made the following trade(s):

• On Monday, August 10th, Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock. The shares were sold at an average price of $10.85, for a total value of $481,674.90.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $12.73 on Friday. The stock has a market cap of $4.94 billion, a P/E ratio of 97.93 and a beta of 1.22. The firm’s 50-day simple moving average is $11.49 and its 200 day simple moving average is $8.80. LifeStance Health Group, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $13.15. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The firm had revenue of $435.35 million during the quarter, compared to analyst estimates of $414.58 million. During the same quarter in the prior year, the firm posted ($0.01) EPS. LifeStance Health Group’s revenue was up 26.1% compared to the same quarter last year. Equities analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Silversmith Partners I GP LLC purchased a new position in shares of LifeStance Health Group in the fourth quarter worth approximately $100,842,000. First Eagle Investment Management LLC raised its holdings in shares of LifeStance Health Group by 13.3% during the fourth quarter. First Eagle Investment Management LLC now owns 1,496,466 shares of the company’s stock worth $10,535,000 after acquiring an additional 176,000 shares in the last quarter. Moran Wealth Management LLC acquired a new stake in shares of LifeStance Health Group during the 1st quarter valued at about $953,000. Orbimed Advisors LLC bought a new stake in LifeStance Health Group in the first quarter worth approximately $3,185,000. Finally, Renaissance Technologies LLC boosted its holdings in LifeStance Health Group by 92.5% in the first quarter. Renaissance Technologies LLC now owns 800,500 shares of the company’s stock worth $5,099,000 after purchasing an additional 384,600 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LFST has been the topic of several recent analyst reports. Barclays boosted their target price on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 14th. KeyCorp raised their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.38.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.